A Comprehensive Review on the Transmission, Pathogenesis, and Prevention of Monkey Pox

 

Neha Sharma¹*, Sakshi Sharma², Madhu Bala¹, Ritesh Rana¹, Neelam Sharma¹

¹Department of Pharmaceutics, Himachal Institute of Pharmaceutical Education and Research, Nadaun, HP

²Department of Pharmaceutics, Chandigarh Engineering College, CGC, Jhanjeri Mohali

 

ABSTRACT:

Manily the cases of monkeypox connected to the 2022 breakout are being reported in nations throughout Europe and the Western Hemisphere, where it was formerly endemic to parts of Africa. Numerous groups are working on contact-tracing initiatives, but it is still unclear what started this outbreak. The monkeypox virus disease is a zoonotic viruses is a member of the orthopoxvirus genus and belonging to family poxiviridae. Following the eradication of smallpox worldwide in the 1970s, occurrences of monkeypox attracted attention on a global scale. The monkeypox virus could be protected against by the smallpox vaccine. Monkeypox instances increased once the smallpox vaccine was no longer administered. Monkeypox did not really receive widespread notice until the 2003 US outbreak. Despite the name "monkeypox," the virus did not originate in monkeys. The virus has been linked to a numeral of rodents and small animals, but the exact source of monkeypox is still unknown. The viral infection was originally noticed in macaque monkeys, hence the term "monkeypox." Although transmission of monkeypox from person to person is extremely uncommon, it is frequently assign to respiratory secretions or closely contacted with mucocutaneous abrasion of the contaminated person. Now present no designated cure for contaminated person, although supportive therpy may be used to relieve symptoms; in extremely severe cases, medications such tecovirimat may be used. Because there are no precise recommendations for symptom alleviation, many treatments are arbitrary. In light of the current outbreaks worldwide, we provide updated information on monkeypox for healthcare professionals in this review.

 

 

 

INTRODUCTION:

Monkeypox, presently a rare zoonotic infection, is cause by the monkeypox virus, which belonging to the Poxviridae family, Chordopoxvirinae subfamily, and Orthopoxvirus genus¹. Monkeypox sickness caused a smallpox-like sickness because the variola virus which causes smallpox is closely linked¹. According to historical statistics, smallpox immunisation with the vaccinia virus (another orthopoxvirus) provided about Eighty-five percent protection against monkeypox².

 

 

However, in 1980 after smallpox was eliminate, schedule immunization against smallpox was no longer suggested³, and it has now been four decades since any orthopoxvirus vaccination programme.

 

The virus was initial recognized in monkeys in a Danish laboratory in 1958, hence the term monkeypox⁴. In Zaire (now the Democratic Republic of the Congo, DRC), a 9-month-old boy was found to have the earliest human case in 1970⁵. Even then, monkeypox has outspread to other African nations, primarily in Central and West Africa, and has become endemic in the DRC. The first instances of monkeypox outside of Africa were documented in 2003⁶, and most recent cases were reported in 2019^7,8 .

 

Viruses are still responsible for a greater number of medically significant emerging and reemerging infection, and also responsible for variety of human and animal contagious diseases. They are a far more serious risk to worldwide public health today than they were a century ago. Viruses caused the mostly fear and fatal human disease, also their rapid spread contributes significantly to global contagious disease morbidity and mortality^9,10. Furthermore, a variety of viruses can be used as both biological and chemical weapons^11-14. As the world commemorates the abolition of smallpox four decades ago, Nigeria recently experienced an outbreak of a severe skin rash which is caused by the monkeypox virus (MPXV), which mimics both varicella zoster and smallpox¹⁵.

 

Poxviruses have a strong propensity to arise outer their typical ecological limit through transmission to naive people because half of the world's people lacks protection to orthopoxviruses^16-17. It can be demonstrated by the growing size and rate of epidemic outbreak of another orthopoxvirus diseases, such as cow-pox and buffalo-pox, with the current outbreak in Nigeria further validating earlier reports of person to person transmission of monkeypox viruses^18-20.

 

The poxviruses belonging to family Poxviridae. Poxviruses is a double-stranded (dsDNA) DNA .Poxviruses have very huge genomes (130–360 kb in length), usually encoding more than 150 genes per genome²¹. The Poxviridae are classify into two subfamily: Entomopoxvirinae, infect insect; and Chordopoxvirinae, infect vertebrate²² and 16 genera²³. There are 2 subfamilies of virus based on range of host, these are Chordopoxvirinae, which cause infection in vertebrates, and other one is a Entomopoxvirinae, which cause infection in insect. In the previous group, a number of pathogen viruses (eg, monkey-pox, cow-pox, and tana-pox) infect birds and animals, such as monkeys, cows and etc and sometimes transmitted and caused infection in humans.²⁴ replication of Poxvirus occur in the cell cytoplasm, which prevents the virus from to use the nuclear enzymes of host and require it to encode its own enzyme for DNA replica. Replication of DNA is essential to provide DNA template from which in-between gene product can be express and than regulate the late transcription process give the virion protein²⁴. The presence of at least a fraction of the viral life cycle in the host cytoplasm is a feature shared by all members of the Nucleo-Cytoplasmic Large DNA Viruses, a proposed clade of eukaryotic huge DNA viruses^25,26. Figure no 1.

 

Figure No 1:- Structure of Monkeypox virus²⁷

 

OUTBREAKS:

The monkeypox virus first case was diagnosed in 9 month aged baby boy and in Democratic Republic of the Congo, where small-pox had been eradicated in 1968. Majority of human cases have been recorded from central and west Africa and large number of cases come from the rural area, rain forest area of the Congo Basin, mostly in the Democratic Republic of the Congo. Benin, Cameroon, the Central African Republic, the Democratic Republic of the Congo, Gabon, Cote d'Ivoire, Liberia, Nigeria, the Republic of the Congo, Sierra Leone, and South Sudan are the eleven African nations where cases of human monkeypox virus recorded since 1970. For example, For instance, an epidemic with a least case fatality ratio and a higher rate of attack than typical was reported in the Democratic Republic of the Congo in 1996–1997. The outbreaks of Monkeypox and chickenpox occurred at the same time in this instance could be described by real modification or apparent modification in the dynamics of transmission produced by the varicella virus, that is not an orthopox virus. About 500 suspicious cases, over 200 completely confirm cases, and a case fatality rate of about three percent have been recorded in Nigeria 2017 and cases are still being recorded today.

 

Even the nation which are affecting with monkeypox that are west and central Africa have a significant effect on whole world and public health. Another case of monkeypox virus other than west and central Africa was seen in the United States in 2003 and was assigned to get in touch with pet dogs prairie that were infected. These animals had been housed alongside imported dormice and pouched rats from Ghana that were from the Gambia. In the U.S., this outbreak caused more than 70 cases of monkeypox. Additionally, travelers from Nigeria to Israel in September 2018, the United Kingdom in September 2018, the U.S.in December 2018, Singapore in May 2019, and the United Kingdom in May 2021 and May 2022 have reported having monkeypox. Monkeypox cases were found in a number of non-endemic nations in May 2022. Today the study was conducted continuously to know the more about the cause of disease, how the disease is transmitted and epidemiology of disease²⁸ .

 

Situation at a glance:

Confirmation of monkeypox cases was done by two diagnostic laboratory and one of the possible cases of virus from the home in the United Kingdom were reported to WHO on May 13, 2022. Four further occurrences of the vesicular rash sickness in men who done sex with men four cases that have been confirmed in the lab among clients of the Sexual Health Services have been recorded as of May 15. An incident group of people has been formed to managet tracing initiatives as part of reaction measures.

 

In contrast to occasional instances linked to travel to endemic nations, the origin of the disease has not yet been identified. According to the information that is currently available, the infection in the United Kingdom appears to have been picked up locally. There is a chance that more cases will be found, and the degree of local transmission is currently unknown^29.

 

Description of the cases:

Two monkeypox cases that were confirmed in the lab and one case that was considered likely were reported to WHO by the United Kingdom on May 13, 2022. The same family includes all three of the cases.

 

Epidemiological evidence links the two confirmed instances and the likely case, which has completely recover. The first patient discovered (index case) manifested a rash dated on May 5 and was hospitalised in London, England, dated on May 6. The case was moved to a specialised infectious illness centre on May 9 for continued care. On May 12, monkeypox was confirmed. Another verified case experienced a vesicular rash on April 30 and was diagnosed with monkeypox on May 13. They are still in stable condition. Using vesicle swabs on May 12 and May 13, (RT PCR) reverse transcriptase polymerase chain reaction was used to find out the two confirmed cases of monkeypox's West African clade. Four more laboratory-confirmed cases of MSM accessing Sexual Health Services and exhibiting a vesicular rash were reported to WHO on May 15^th30 .

 

TRANSMISSION:

Endemic and nonendemic transmission of monkeypox virus are given in Figure 2.

 

1.     Transmission by Animal-to-human (zoonotic):- Directly contacted with the various body fluids, blood, cutaneous lesions, or mucosal lesions of infectious animals as well as bites and scratches from infectious animals can lead in transmission to animal-to-human (zoonotic). Spreading may also occur during the formulation and handling of contaminated animal by-product (such as meat³¹). There is no known definitive animal reservoir for MPXV. Small mammals and non human primates are among the animal species from which the virus has been isolated. The animals had lesions like a pox that have consistent with active infection in the documented cases where Monkeypox virus has been isolated from wild animals^32–34. It is unknown if MPXV is carried asymptomatically in animal reservoirs. Wild mammals have been the subject of serological studies in endemic areas. These research have discovered that a number of animal species contain OPXV antibodies that can be detected even in the absent of viremia as determined by reaction that is called as polymerase chain reaction (PCR) testing. This shows that numerous wild animal species are exposed to and are exposed to the zoonotic OPXV^35-36.

 

2.     Human-to-human transmission:-

In human to human transmission there is a Closed contacted with human respiration secretion, skin sore on an contaminated human being, and recently infected things can cause human-to-human transmission. Health care worker, various family people, and other close contacts of present patients are mostly at risk because droplet respiratory particles typically require extended man to man contact. The number of human-to-human infection in a community's longest documented chain of transmission has increased from last six to nine in recent years. This might be an indication of a general reduce in immunity brought on by the end of smallpox vaccination campaigns. Congenital monkeypox can result through transmission through the placenta, which can also happen during intimate touch during birth and after birth. Although closed contact is a known risk factor for the spreading, it is not known at this time whether monkeypox can particularly spread through sexual intercourse. Study’s are required to comprehend this risk better^37.

 

 

Figure No 2:- Transmission of human monkeypox.

 

In endemic regions, zoonotic animal reservoirs can spill over into human populations, potentially causing small-scale epidemics that are frequently aided by close human contact. The virus can spread through human travel or the import of animals that have virus can potentially cause outbreaks in areas where it is not endemic. Then, through home connections and other close relationships, human-to-human transmission can take place^38.

 

PATHOGENESIS:

Whether the virus is transmitted from human-to-human or from animal-to-human, the aetiology and pathophysiology of monkeypox start with this transmission. Respiratory droplets are the most frequent source of man-to-man transmission. Directly contacted with infected people's mucocutaneous lesions as well as contact with contaminated objects or surfaces are listed in Figure No 3. Similar to smallpox, the infectious process for monkeypox virus starts with exposure to the host's oropharyngeal or respiratory mucosa. The replication of monkeypox virus at the inoculation site after viral entrance; in people-to-people transmission, the inoculation site is the respiration system and oropharyngeal mucosa.

 

In primary or prime viremia, first the viral load multiplies and then spreading to the primary lymphatic nodes. In secondary viremia, the viral load travels through circulation to distant lymphatic nodes and organs. This procedure reflected the incubation phase, which can take up to 21 days and normally lasts seven to fourteen days^39. Monkeypox does not have clinical manifestation during the incubation stage, hence this phase is not communicable. The prodromal stage is a stage which is primary associated to monkeypox symptoms and clinical manifestation. Spreading of secondary viremia from the lymphatic system to the skin and tertiary organs including the lungs, eyes, GIT, etc. throughout the prodromal phase. A person is considering being the most infection during the prodromal stage. This is mostly because of symptoms like lymphadenopathy (swelling of lymph nodes) and mucocutaneous lesions, among other non-specific symptoms.

 

Figure 3: Pathogenesis of Monkeypox

SIGNS AND SYMPTOMS:

Mainly the symptom of virus (monkeypox) typically take 6 days to 13 days but vary from 5 to 21 days.

The infection can be classified into two stages:

·       During the prodromal stage or the invasion period (lasts between 0–5 days) non-specific symptoms trigger the immune response like fever, lymphadenopathy (swelling of the lymph nodes), myalgias (muscle aches), back pain and intense asthenia (lack of energy) . Lymphadenopathy is a distinctive feature of monkeypox compare to further disease that may show similar like (chickenpox, measles, smallpox). Due to the non-specific nature of this early symptom, a contaminated person may attribute this symptom to seasonal cold or the common flu. First activation of the immune system will always responsibal for enlargement of lymphatic node, include maxillary, cervical and inguinal, occurring in synchrony with the onset of fever^40.

·       The skin eruption often started with in one to three days after fever. Instead of the trunk, the rash is mainly seen on the face of the contaminated person and limbs. The rash that is seen on infected people presents in a very specific way. The diffused vesiculo pustular rash is the defining characteristic of monkeypox^41.

 

Figure No. 4 :-Nonspecific Symptoms and Complications of Monkeypox

 

Before the rash enters the desquamation phase, during this the scabs start to peel off, it has been observed that it goes through a number of stages. These characteristic lesions frequently manifest as enanthem, macular, papular, followed by vesicular and pustular lesions. The lesions are more painful in all levels listed in Figure No. 5^42,37. Within two to three weeks, these lesions will crust over^43.

 

 

Figure No.5: Various stages of the vesiculo-pustular rash in patients

A person will notice lesions forming on the tongue and mouth before the rash manifests on the skin; these lesions are referred to as enanthem. A person is no longer regarded as infectious once the crusted lesions peel off to expose new skin underneath. The desquamation phase is known as this. When scabs peel off, people can have scars left behind. Some people might even have spots where the rash was highly concentrated that are hyperpigmented and hypopigmented. All of the stages of the lesions shown in Figure no. 5 are painful, except for the desquamation stage, where the crusting is extremely itchy. Epidermal necrosis is found at the core of person lesion, concurrent with nascent extension into the surface layer of the dermis, according to histopathological examination of the early stage of lesion developing in people^41,44. Non-human primates with monkeypox infection have similarly shown increased lesion pathology when pustules grow, including progressive ulceration, necrosis, and interstitial hyperplasia^43. Additionally, clefts form in the intercellular gaps where fluid and cellular debris collect, and edema is noticeable at the edges of necrotic areas^40,44. Eventually, the superficial dermis becomes mostly inflamed and necrotic, and sebaceous glands and follicles are clearly destroyed ^[44].The combination of these characteristics causes the damaged areas to be labeled as "partial-thickness wounds," and an wound of this magnitude indicates the necessity for proactive preventive of consequences including secondary bacterial infection and potential cellulitis^41,44. Interventional study have shown that moist occlusive therapy effectively promote re-epithelialization and heal at herpes lesions site,and as a result, the use of moist occlusive dressings may be considered for person who have rash lesions that cover a large portion of their faces^41,45_.

 

DIAGNOSIS:

Clinicians should enquire about the patient's sexual and travel history, as well as any close encounters with individuals who have a same rash or who have a suspect or confirme monkeypox illness. Resting in the similar room, drinking or ingestion from the similar vessel, residing in the similar home, etc. are actions associated with close contact^46. More crucially, the likelihood of this diagnosis should not be ruled out due to lack of travel history, lack of a particular identified close contact with a rash, or lack of a suspect or confirmed monkeypox case. Additionally, a complete skin examination needs to be done.

 

Sample was obtaining from a lesion for PCR molecular testing is the best diagnostic method for a person with suspected active monkeypox illness. In order to appropriately collect virus-containing secretions, lesions should be opened up and multiple specimens should be taken from two distinct lesions on two different areas of the body. While some labs can perform generic OPXV test that necessitates MPXV confirmation test at a reference lab, some labs can only carry out direct PCR testing for MPXV specifically. However, given the circumstances of the current outbreak, it is reasonable to draw the conclusion that monkeypox infection has been detected based on a positive OPXV test even before confirmatory test results are available. Prior to the collection of the sample, the testing strategy should ideally be synchronized with public health system.

 

Only accredited biosafety level 3 reference laboratories are permitted to use cell culture to produce viral strains for further characterisation^47. The detection of late clinical symptoms, such as encephalitis, and retrospective diagnosis of previous infections are all possible uses for serological testing. Even though MPXV serology can cross-react with previous smallpox immunisation, this is not a worry in those who have not received the vaccine^48.

 

TREATMENT:

There isn't a specific medication for the monkeypox virus infection right now. However, a greater number of antiviral drugs use to treat smallpox and other ailments could be beneficial for those with monkeypox infection. The US Food and Drug Administration (FDA) has not yet approve any specific therapies for monkeypox disease.

 

 

Figure No. 5:- Various stages of monkeypox rash skin presentation and progression^38.

 

Table No 1 :- Treatment Options for Monkey Pox Infection

 

However, several antiviral medications, such as cidofovir, brincidofovir (a lipid-conjugate prodrug of cidofovir), and tecovirimat^49, exhibit activity against MPXV⁴⁹ and antiviral drugs, vaccinia immune globulin intravenous (VIGIV) have been approve earlier by the Food and Drug Administration for complications treatment due to vaccinia vaccination, such as progressive vaccinia and severe generalized vaccinia^50. A outline of these treatment given in table 1.

 

PREVENTION:

For those in close touch with an infected patient, preventing monkeypox infection can be difficult. Direct contact with skin lesions or items (such clothing, bedding, and towels) used by patients with monkeypox must be avoided in order to decrease the risk of contamination. Physician should wearing individual protective care, such as a coat, gloves, eye glasses, and a appropriate mask, when caring the person with skin lesions. A person who has monkeypox illness should be immediately cover in a mask, have any lesions cover with a clean coat or sheet, and be isolate in a separate-person room. There is no need for individual air handling requirement, but if a person needs to be admit to the hospital, they must be put in a negative-pressure room if one is existing. Standard cleaning and disinfection techniques are adequate for environmental infection management, however dirty clothing handle with gloves to prevent touching with lesion substance that may be currently present on the laundry. Although the duration is uncertain, immunisation against smallpox is thought to offer up to 85% cross-protection against monkeypox^57. Some public health professionals have proposed that the cessation of routine smallpox immunisation following the disease's eradication in 1980 may be partially to blame for the comeback of monkeypox^58.

 

ACAM2000 and JYNNEOS, a live, non-replicated, modified vaccinia virus Ankara vaccine and are the only legal smallpox vaccinations now existing in the US. JYNNEOS is often referred to as Imvamune or Imvanex. Although the US Food and Drug Administration (FDA) has only approved JYNNEOS as a vaccine to avoid monkeypox, the Advisory Committee on Immunization Practices advises that anyone who has occupational exposure to orthopoxviruses (for example, person who work with virus sample) get either the ACAM2000 or JYNNEOS vaccine as pre exposure prophylaxis.

 

Patients who have been in close touch with someone who is afflicted with the monkeypox virus can also receive the JYNNEOS post exposure vaccination. The CDC advises vaccination up to 14 days after contact to lesion the seriousness of sickness or within 4 days of exposure to avoid disease^[57] The US Strategic National Stockpile currently has about 36 000 doses of the JYNNEOS vaccine. Although the CDC has advised that the JYNNEOS vaccine be given to close relatives of monkeypox virus suffered person, this vaccine is at present difficult to get.

 

Reducing the risk of zoonotic transmission:

With time, primary animal-to-human transmission has been the cause of the maximum of human infection. It is important to prevent insecure contact with wild animal, particularly those that are sick or dead, as well as their tissue, blood, and other by-product. All things contain animal meat or part must also be completely cooked before eating.

 

Preventing monkeypox through restrictions on animal trade:

Some nations have laws in place that limit the import of non-human primates and rodents. Animals kept in captivity that might have monkeypox should be isolated right away and kept separate from other animals. Animals that may have interacted with an contaminated animal need to be confined, handled with regular safety measures, and monitored for signs of monkeypox for 30 days.

 

Health person should always use standard safety measures and conduct a risk assessment to determine whether additional precautions are required. Standard precautions include the following⁵⁹:

·       hand sanitation 

·       respiration hygiene and cough

·       etiquette patient placement

·       individual protecting tools

·       aseptic method 

·       secure injections and sharps injury avoidance

·       environmental clean-up and disinfection 

·       managing of laundry and linen sanitization and reprocessing or reusable patient care substance and apparatus

·       waste managing

 

CONCLUSION:

The monkeypox becoming a global concern because now posing a threat to people all over the world after occasional instances in the western hemisphere were identified. Social isolation and contact tracking are essential since human-to-human transmission typically happens by respiratory droplet or directly touch with the mucocutaneous lesions of a contaminated person. Confirmed cases of monkeypox in people in their mid-twenties. This results from the cross-immunity from the smallpox vaccine that is lost in elderly people. Virus grows and multiplies in the cytoplasm before entering a primary viremia and infecting nearby lymph nodes. Additionally, complications from monkeypox infection include encephalitis, dehydration, respiratory distress, and bronchopneumonia. The corneal scarring issue is the most concerning one because it can cause vision loss. In order to reduce the danger of these problems as much as possible, it is critical to be able to offer the proper supportive care. In places where the rash is heavily concentrated, supportive therapy may be used, such as the application of moist occlusive dressings. organization are concentrating on understand how these cases are intermittently arising across Europe and the western hemisphere as monkeypox virus cases are still being verified globally. It's crucial to look into any viable remedies, as well as comprehend the full scope of every monkeypox symptom and the virus's and symptoms' long-term repercussions.

 

REFERENCES:

1.   (ICTV) ICoToV. Virus Taxonomy: 2020 Release. Available from: https://talk.ictvonline.org/taxonomy

2.   Fine PE, Jezek Z, Grab B, Dixon H. The transmission potential of monkeypox virus in human populations. International journal of epidemiology. 1988; 17(3):643-50.

3.   Jezek Z, Khodakevich LN, Wickett JF. Smallpox and its post-eradication surveillance. Bulletin of the world health organization. 1987; 65(4):425.

4.   Magnus PV, Andersen EK, Petersen KB, Birch‐Andersen A. A pox‐like disease in cynomolgus monkeys. Acta Pathologica Microbiologica Scandinavica. 1959: 46(2):156-76.

5.   Breman JG, Kalisa-Ruti, Steniowski MV, Zanotto E, Gromyko AI, Arita I. Human monkeypox, 1970-79. Bull World Health Organ. 1980; 58(2):165-82. PMID: 6249508; PMCID: PMC2395797.

6.   Centers for Disease Control and Prevention. Monkeypox. Available from: https://www.cdc.gov/ poxvirus/monkeypox/index.html

7.   Public Health England. Monkeypox case confirmed in England 2019. Available from: https://www.gov. uk/government/news/monkeypox-case-confirmed-in-england .\

8.   Howard CR, Fletcher NF. Emerging virus diseases: can we ever expect the unexpected?. Emerging Microbes and Infections. 2012 ; 1(1):1-9.

9.   Yong SE, Ng OT, Ho ZJ, Mak TM, Marimuthu K, Vasoo S, Yeo TW, Ng YK, Cui L, Ferdous Z, Chia PY. Imported Monkeypox, Singapore. Emerging Infectious Diseases. 2020; 26(8):1826.

10. Woolhouse ME, Gowtage-Sequeria S. Host range and emerging and reemerging pathogens. Emerging infectious diseases. 2005 Dec; 11(12):1842.

11. Miller S, Selgelid MJ. Ethical and philosophical consideration of the dual-use dilemma in the biological sciences. Science and Engineering Ethics. 2007; 13:523-80.

12. Selgelid MJ, Weir L, Jackson R, Ramshaw I. The mousepox experience: an interview with Ronald Jackson and Ian Ramshaw on dual‐use research. EMBO Reports. 2010; 11(1):18-24.

13. Evans NG. Dual-use decision making: relational and positional issues. Monash Bioethics Review. 2014; 32:268-83..

14. Webster RG. Mammalian-transmissible H5N1 influenza: the dilemma of dual-use research. MBio. 2012 Mar 1; 3(1):e00005-12.

15. MacNeil A, Reynolds MG, Braden Z, Carroll DS, Bostik V, Karem K, Smith SK, Davidson W, Li Y, Moundeli A, Mombouli JV. Transmission of atypical varicella-zoster virus infections involving palm and sole manifestations in an area with monkeypox endemicity. Clinical Infectious Diseases. 2009; 48(1):e6-8.

16. Mazurkov OY, Kabanov AS, Shishkina LN, Sergeev AA, Skarnovich MO, Bormotov NI, Skarnovich MA, Ovchinnikova AS, Titova KA, Galahova DO, Bulychev LE. New effective chemically synthesized anti-smallpox compound NIOCH-14. Journal of General Virology. 2016; 97(5):1229-39.

17. Reed KD, Melski JW, Graham MB, Regnery RL, Sotir MJ, Wegner MV, Kazmierczak JJ, Stratman EJ, Li Y, Fairley JA, Swain GR. The detection of monkeypox in humans in the Western Hemisphere. New England Journal of Medicine. 2004; 350(4):342-50.

18. Favier AL, Flusin O, Lepreux S, Fleury H, Labrèze C, Georges A, Crance JM, Boralevi F. Necrotic ulcerated lesion in a young boy caused by cowpox virus infection. Case Reports in Dermatology. 2011; 3(3):186-94.

19. Formenty P, Muntasir MO, Damon I, Chowdhary V, Opoka ML, Monimart C, Mutasim EM, Manuguerra JC, Davidson WB, Karem KL, Cabeza J. Human monkeypox outbreak caused by novel virus belonging to Congo Basin clade, Sudan, 2005. Emerging Infectious Diseases. 2010; 16(10):1539.

20. Kugelman JR, Johnston SC, Mulembakani PM, Kisalu N, Lee MS, Koroleva G, McCarthy SE, Gestole MC, Wolfe ND, Fair JN, Schneider BS. Genomic variability of monkeypox virus among humans, Democratic Republic of the Congo. Emerging infectious Diseases. 2014; 20(2):232.

21. Lefkowitz EJ, Wang C, Upton C. Poxviruses: past, present and future. Virus Research. 2006; 117(1):105-18.

22. Van Regenmortel MH, Fauquest CM, Bishop DH, Carstens EB, Estes MK, Lemon SM, Maniloff J, Mayo MA, McGoech DJ, Pringle CR, Wickner RB. Virus Taxonomy. Academic Press; San Diego: 2000.

23. Van Regenmortel MH. Virus taxonomy. Classification and nomenclature of viruses. Seventh report of the International Committee on Taxonomy of Viruses. 2000:395-480.

24. Poxviridae. ICTV 9th report (2011) International Committee on Taxonomy of Viruses.https://talk.ictvonline.org/ictv reports/ictv_9th_report/dsdna viruses 2011/w/dsdna_viruses/74/poxviridae. Accessed 27 August 2018).

25. Iyer LM, Aravind L, Koonin EV. Common origin of four diverse families of large eukaryotic DNA viruses. J Virol. 2001; 75:11720–11734.  

26. Iyer LM, Balaji S, Koonin EV, Aravind L. Evolutionary genomics of nucleo-cytoplasmic large DNA viruses. Virus Research. 2006; 117:156–184.  

27. Sklenovská, N. (2020). Monkeypox Virus. Livestock Diseases and Management, 39 68 https://doi.org/10.1007/978-981-15-2651-0_2

28. World Health Organization. Monkeypox 2019 [updated December 9, 2019]. Available from: https://www.who.int/news-room/fact-sheets/detail/monkeypox

29. World Health Organization (16 May 2022). Disease Outbreak News; Monkeypox– United Kingdom of Great Britain and Northern Ireland. Available at: https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON381

30. World Health Organization (18 May 2022). Disease Outbreak News; Monkeypox– United Kingdom of Great Britain and Northern Ireland. Available at: https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON383

31. Meyer H, Perrichot M, Stemmler M, et al. Outbreaks of disease suspected of be- ing due to human monkeypox virus infection in the Democratic Republic of Congo in 2001. J Clin Microbiol 2002; 40:2919–21. doi:10.1128/JCM.40.8. 2919-2921.2002

32. Khodakevich L, Jezek Z, Kinzanzka K. Isolation of monkeypox virus from wild squirrel infected in nature. Lancet. 1986; 1:98–9. doi:10.1016/S0140-6736(86) 90748-8

33. Radonić A, Metzger S, Dabrowski PW, et al. Fatal monkeypox in wild-living sooty mangabey, Côte d’Ivoire, 2012. Emerg Infect Dis 2014; 20:1009–11. doi: 10.3201/eid2006.131329

34. Patrono LV, Pléh K, Samuni L, et al. Monkeypox virus emergence in wild chim- panzees reveals distinct clinical outcomes and viral diversity. Nat Microbiol 2020; 5:955–65. doi:10.1038/s41564-020-0706-0

35. Falendysz EA, Lopera JG, Doty JB, et al. Characterization of monkeypox virus infection in African rope squirrels (funisciurus sp.). PLoS Negl Trop Dis 2017; 11:e0005809. doi:10.1371/journal.pntd.0005809

36. Doty JB, Malekani JM, Kalemba LN, et al. Assessing monkeypox virus preva- lence in small mammals at the human-animal interface in the Democratic Republic of the Congo. Viruses 2017; 9:283. doi:10.3390/v9100283

37. Di Giulio DB, Eckburg PB. Human monkeypox: an emerging zoonosis. Lancet Infect Dis 2004; 4:15–25. doi:10.1016/S1473-3099(03)00856-9

38. Boghuma K Titanji, Bryan Tegomoh, Saman Nematollahi, Michael Konomos, Prathit A Kulkarni, Monkeypox: A Contemporary Review for Healthcare Professionals, Open Forum Infectious Diseases. 2022;  9(7)::310, https://doi.org/10.1093/ofid/ofac310

39. Moore M, Zahra F: Monkeypox. StatPearls [Internet], Treasure Island (FL); 2022.

40. Okyay RA, Bayrak E, Kaya E, et al.: Another epidemic in the shadow of Covid 19 pandemic: a review of monkeypox. EJMO. 2022, 6:95-9. 10.14744/ejmo.2022.2022

41. Reynolds MG, McCollum AM, Nguete B, Shongo Lushima R, Petersen BW: Improving the care and treatment of monkeypox patients in low-resource settings: applying evidence from contemporary biomedical and smallpox biodefense research. Viruses. 2017, 9:380. 10.3390/v9120380

42. McCollum AM, Damon IK: Human monkeypox. Clin Infect Dis. 2014, 58:260-7. 10.1093/cid/cit703

43. Afshar ZM, Rostami HN, Hosseinzadeh R, et al.: The reemergence of monkeypox as a new potential health challenge: a critical review. Ann Med Surg. 2022, 78:

44. Stagles MJ, Watson AA, Boyd JF, et al.: The histopathology and electron microscopy of a human monkeypox lesion. Trans R Soc Trop Med Hyg. 1985, 79:192-202. 10.1016/0035-9203(85)90333-5

45. Patel AR, Romanelli P, Roberts B, Kirsner RS: Herpes simplex virus: a histopathologic study of the depth of herpetic wounds. Int J Dermatol. 2009, 48:36-40. 10.1111/j.1365-4632.2009.03788.x

46. Bunge EM, Hoet B, Chen L, et al. The changing epidemiology of human monkeypox-a potential threat? A systematic review. PLoS Negl Trop Dis 2022; 16:e0010141. doi:10.1371/journal.pntd.0010141

47. Centers of Disease Control and Prevention. Biosafety in Microbiological and Biomedical Laboratories. Editors PJ Meechan and J Potts). 6th ed. Available at: https://www.cdc.gov/labs/pdf/CDC-BiosafetyMicrobiologicalBiomedicalLaboratories- 2020-P.pdf. Accessed 17 June 2022.

48. Hammarlund E, Lewis MW, Carter SV, et al. Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox. Nat Med 2005; 11:1005–11. doi:10.1038/nm1273

49. Grosenbach DW, Honeychurch K, Rose EA, et al. Oral tecovirimat for the treat- ment of smallpox. N Engl J Med 2018; 379:44–53. doi:10.1056/NEJMoa1705688

50. Wittek R. Vaccinia immune globulin: current policies, preparedness, and prod- uct safety and efficacy. Int J Infect Dis 2006; 10:193–201. doi:10.1016/j.ijid.2005. 12.001

51. James JS. Cidofovir recommended for approval for CMV retinitis. AIDS Treat News 1996; (no 244):6–7.

52. Lederman ER, Davidson W, Groff HL, et al. Progressive vaccinia: case descrip- tion and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001. J Infect Dis 2012; 206:1372–85. doi:10.1093/infdis/jis510

53. US Food and Drug Administration. FDA approves the first drug with an indica- tion for treatment of smallpox. Rockville, MD: US Food and Drug Administration; July 13, 2018 (News Release). Available at: https://www.fda.gov/ news-events/press-announcements/fda-approves-first-drug-indication-treatment- smallpox. Accessed 15 June 2022.

54. Centers for Disease Control and Prevention. Guidance for Tecovirimat Use Under Expanded Access Investigational New Drug Protocol during 2022 U.S. Monkeypox Cases. Available at: https://www.cdc.gov/poxvirus/monkeypox/ clinicians/Tecovirimat.html. Accessed 15 June 2022.

55. US Food and Drug Administration. FDA approves drug to treat smallpox. Rockville, MD: US Food and Drug Administration; June 4, 2021 (News Release). Available at: https://www.fda.gov/drugs/news-events-human-drugs/ fda-approves-drug-treat-smallpox. Accessed 15 June 2022.

56. CIDRAP. FDA approves VIG for smallpox shot complications. Available at: https://www.cidrap.umn.edu/news-perspective/2005/02/fda-approves-vig-smallpox- shot-complications. Accessed 16 June 2022.

57. Centers for Disease Control and Prevention. Monkeypox and smallpox vaccine guidance. Accessed June 9, 2022. https://www.cdc.gov/poxvirus/monkeypox/clinicians/smallpox-vaccine.html

58. Rimoin AW, Mulembakani PM, Johnston SC, et al. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo.  Proc Natl Acad Sci U S A. 2010; 107(37):16262-16267. doi:10.1073/pnas.1005769107PubMedGoogle ScholarCrossref

59. Guidelines on core components of infection prevention and control programmes at the national and acute health care facility level. Geneva: Health Organization; 2016 (https://apps.who.int/iris/handle/10665/251730, accessed 9 June 2022)

 

 

 

 

Received on 21.09.2023         Modified on 09.12.2023

Accepted on 11.01.2024   ©A&V Publications All right reserved